secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001516551-23-000046
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 2.03, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience acquires Bird Rock Bio in $17M financing, gains Phase 2 CB1 antibody nimacimab
--------------------------------------------------------------------------------

- Acquired Bird Rock Bio; lead asset nimacimab is a phase 2-ready peripherally-restricted CB1 inhibitor for glaucoma and CKD.
- Raised $17M: $12M PIPE (581M shares at $0.0206) and $5M convertible note from MFDI, with 10-year warrants.
- Post-merger ownership: Bird Rock holders ~31.4%, PIPE investors ~37%, legacy Skye ~31.6%; ~3.08B shares outstanding.
- Appointed Andrew Schwab (5AM Ventures) and Paul Grayson (ex-Bird Rock CEO) to board; Schwab on compensation committee.
- Posted $9.08M appeal bond in Cunning wrongful termination lawsuit; announced intention to effect reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000046/0001516551-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000046/skye-20230815.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer